297 results about "Controlled drugs" patented technology

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

A three-dimensional scaffold for use in engineered tissue includes a repeated 3D geometry; and at least one of a hydrogel, a biocompatible polymer, and a bioprintable polymer. The repeated 3D geometry may include an open geometry including a plurality of interconnected nodes configured to be seeded with living cells. The scaffold may be formed via bioprinting. The three-dimensional scaffold may also be used for (1) 3D tissue modelling (for liver, kidney, gut, pancreas, heart, lung, spleen, etc.), (2) disease modeling of different tumor types such as breast, colorectal, lung, liver, brain, ovarian and others, (3) drug testing / therapeutic screening of small molecule drugs, peptides, proteins, antibodies, ADCs, gene therapies, RNA-based therapeutics, cell therapies, and tissue therapies, and (4) therapeutic / drug delivery (i.e., via delivery device that can be used to control drug release based on different patterns).

An emulsion comprises a first discontinuous phase comprising first droplets, a second discontinuous phase comprising second droplets, and a continuous aqueous phase. The first droplets include at least one first surfactant and at least one first fluorocarbon, and have a first diameter of more than 100 nm. The second droplets include at least one surfactant, at least one drug, and at least one solvent, and have a second diameter of no more than 100 nm.

The invention relates to the field of biological medicine, in particular to IMSFs hydrogel, a ferroptosis induction system, a preparation method and application. The IMSFs hydrogel comprises a hydrogel body, and ferroferric oxide nanoparticles and sorafenib are loaded in the hydrogel body in a wrapping manner. The IMSFs hydrogel can be used as an injectable cascade ferroptosis anti-cancer drug. The preparation method of the IMSFs hydrogel comprises the following steps: firstly, preparing a silk fibroin-hyaluronic acid hydrogel body: dissolving silk hydrogel and hyaluronic acid in a lithium bromide solution; bDDE is added into the dissolved solution, and incubation is carried out; then dialyzing and washing with deionized water to obtain a silk fibroin-hyaluronic acid hydrogel body; and then loading the sorafenib nanoparticles and the ferroferric oxide nanoparticles into the silk fibroin-hyaluronic acid hydrogel body. The IMSFs hydrogel disclosed by the invention integrates magnetic thermal response and drug controlled release, and can be injected to a tumor site, so that the treatment effect on TNBC is remarkably improved.

Described herein are compositions, systems, and methods for targeted and controlled drug release. In some embodiments, the compositions, systems, and methods may comprise magnetoelectric silica nanoparticles for targeted and controlled release of chemotherapeutic drugs for cancer treatment. In some embodiments, an external magnetic field may be used to release one or more drugs from the magnetoelectric silica nanoparticles. The disclosed compositions, systems, and methods may improve drug targeting and reduce systemic drug toxicity.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

The embodiment of the invention provides breast cancer targeting nanoparticles as well as a preparation method and application thereof. According to the embodiment of the invention, the breast cancer targeting nanoparticles are synthesized by preparing the pH sensitive polymer, carrying out co-coupling modification on the pH response polymer and the folic acid albumin nano-carrier and utilizing a controlled desolvation method; the breast cancer targeting nanoparticle is combined with a nano preparation passive targeting strategy, a tumor microenvironment stimulation response strategy and a folic acid active targeting strategy, the effects of an EPR effect, PEG shedding, charge overturning, folic acid ligand-receptor combination and the like are utilized, precise targeting and specific response of tumors are achieved, and targeted accumulation of drugs in a tumor microenvironment is comprehensively improved. Therefore, the breast cancer targeting nanoparticles prepared by the embodiment have the advantages of high targeting property, drug controlled release, improvement of solubility and absorptivity of indissolvable drugs and the like, so that the curative effect of the drugs can be enhanced, the toxic and side effects can be reduced, and the breast cancer targeting nanoparticles have wide application prospects in the field of anti-tumor treatment.

The invention belongs to the technical field of nano-carriers, and particularly relates to a casein-based nano-carrier with slow release and pH / NIR dual response as well as a preparation method and application thereof, casein is combined with hollow copper sulfide nano-particles to load drugs, the nano-carrier with slow release and pH / NIR dual response is generated, and the drug loading rate is as high as 96.84%. Experiments show that the nano-carrier can accurately control drug release under specific pH and near-infrared light irradiation, so that the drug treatment efficiency is improved, and side effects on normal tissues are reduced.

The invention provides a semeglutide long-acting sustained release microsphere and a preparation method of the semeglutide long-acting sustained release microsphere. According to the method, the semeglutide long-acting sustained-release microspheres are prepared based on a water-in-oil-in-oil (W / O / O) phase separation method. According to the method, the problems of low drug loading capacity and high burst release of a water-in-oil-in-water (W1 / O / W2 type) multiple emulsion method are solved; meanwhile, the particle size of the long-acting and sustained-release microspheres of the semeglutide is between 10 microns and 300 microns, the particle size distribution Span value is between 0.5 and 1.5, and compared with a control drug, the long-acting and sustained-release microspheres of the semeglutide have no burst release effect and no drug release lagging stage after being administrated, have the same onset time as the control drug in an animal body, can be slowly released for one month and have a remarkable blood glucose reducing effect.

Embodiments of the present invention relate to mechanically-activated microcapsules (MAMCs) for controlled drug-delivery, wherein the MAMCs release one or more active ingredients in response to mechanical stimuli in a subject's body. The MAMCs provide a platform for stimulating biological regeneration, biological repair, modifying disease, and / or controlling disease in mechanically-loaded musculoskeletal tissues.

The invention discloses a drug targeted delivery device and method, and belongs to the technical field of intelligent medical treatment. The device comprises the following modules: an intelligent targeted recognition module for accurately recognizing a gastric cancer specific molecular marker and improving the selectivity and specificity of targeted recognition in combination with a dynamic surface modification strategy; the microenvironment real-time monitoring module is used for monitoring key physiological parameters of the gastric cancer microenvironment in real time; the intelligent path planning module is used for dynamically calculating and optimizing a drug delivery path and realizing accurate drug positioning; the personalized drug administration regulation and control module is used for accurately predicting the drug dosage demand of an individual and dynamically and finely adjusting the drug administration amount in real time; the drug resistance risk management module is used for early warning a drug resistance risk in advance and automatically generating a personalized alternative drug administration strategy through multi-dimensional drug resistance analysis and real-time early warning; and the intelligent drug release module adopts a temperature-sensitive / pH-sensitive polymer shell layer and a nano valve to control drug release, so that precise gradient release of drug concentration is realized.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a 2-aminopyrimidine compound, application thereof and an antitumor drug. The 2-aminopyrimidine compound provided by the invention has a structure as shown in a formula (I). According to the invention, 2-aminopyrimidine is used as a mother nucleus structure, and a series of 2-aminopyrimidine compounds are successfully constructed by accurately introducing a biologically active imidazole, thiazole or oxazole nitrogen-containing heterocyclic ring fragment at the 5 # site of 2-aminopyrimidine; systematic in-vitro anti-tumor activity evaluation proves that the 2-aminopyrimidine compound with the structure as shown in the formula (I) provided by the invention shows remarkable inhibitory activity on various tumor cell lines, and the activity of part of the compound is even superior to that of a clinical control drug. The structural diversity of 2-aminopyrimidine compounds is enriched, valuable lead compounds are provided for developing novel efficient antitumor drugs, and the 2-aminopyrimidine compounds have important scientific significance and clinical transformation potential. # imgabs0 #

The invention belongs to the technical field of nano-medicines and targeted therapy, and particularly relates to a targeted nano-system nano-drug delivery system based on mesoporous polydopamine as well as a preparation method and application thereof, in particular to an N2E4-MPDA-Gem nano-system based on mesoporous polydopamine (MPDA). A targeting nano system based on mesoporous polydopamine comprises mesoporous polydopamine nano particles loaded with pancreatic cancer chemotherapy drugs, targeting molecules N2E4 are combined with the surfaces of the mesoporous polydopamine nano particles, and phenylboronic acid coatings used for controlling drug release are arranged on the surfaces of the mesoporous polydopamine nano particles. The system adopts a modular design, can be compatible with various chemotherapeutic drugs such as oxaliplatin, irinotecan and the like, and can be flexibly coupled with different targeting antibodies such as EGFR (epidermal growth factor receptor), HER2 (human epidermal growth factor receptor) and the like. A standard preparation process and good stability provide reliable guarantee for clinical transformation, and the compound shows an excellent treatment effect in a solid tumor model represented by pancreatic cancer.

The invention relates to the technical field of biology, in particular to silymarin inclusion compound lipidosome and a preparation method and application thereof. The silymarin inclusion compound liposome is prepared from the following components in parts by weight: 10 to 48 parts of silymarin, 10 to 53 parts of phospholipid, 5 to 10 parts of Arabic gum and 25 to 70 parts of cyclodextrin. According to the invention, cyclodextrin and phospholipid are combined to form a double-drug-loading structure; on the basis, Arabic gum is used as a film-forming agent to form a protective film on the surface of the liposome, so that the stability of the system is further improved; the silymarin inclusion compound is encapsulated in a water phase in the liposome, and meanwhile, part of free silymarin is encapsulated in a lipid bilayer. According to the structure, the solubility and the encapsulation efficiency of the silymarin are remarkably improved, the liposome stability is enhanced, the drug release is effectively controlled, and the silymarin inclusion compound lipid is simple in preparation process and suitable for industrial production.

The invention discloses a formula and a preparation process of a synthetic biotechnology-based endowed netting loss-control pesticide fertilizer, and relates to the technical field of fertilizers, the loss-control pesticide fertilizer is prepared from the following components by weight: 60-80 parts of a compound fertilizer, 10-20 parts of diammonium phosphate, 2-10 parts of trace elements, 2-8 parts of modified attapulgite, 1-4 parts of an insecticide, 0.5-3 parts of polyglutamic acid, and 1-5 parts of polyvinyl alcohol; according to the invention, a high-efficiency netting loss control system is formed through the energization of polyglutamic acid and the synergistic effect of multiple components, so that not only are the problems of easy nutrient loss and poor pesticide stability in the traditional pesticide fertilizer solved, but also the synergistic slow release of nutrients and pesticide is realized, the utilization rate of the fertilizer is remarkably increased, the control period of the pesticide is remarkably prolonged, and the application value is good.

The invention discloses a self-driven diagnosis and treatment integrated microneedle array paper-based chip as well as a preparation method and application thereof, and belongs to the technical field of biomedicine. The microneedle array chip system comprises a function integration module which at least comprises a self-powered extraction unit, a sensing detection unit and a controlled drug delivery unit. According to the microneedle array paper-based chip, biomarkers in skin interstitial fluid are efficiently collected based on a self-powered thermoelectric chemical battery microneedle, PtPB (at) PEG (at) HA nanoparticles loaded on an immunochromatography test strip combination pad are triggered to be subjected to ring opening, a hybridization chain reaction is induced to generate DNA nano-enzyme, and TMB is catalyzed to develop color; the open-loop nanoparticles can be used for SERS cross detection of biomarkers, and can be used as a thermal initiator to activate the phase change microneedle under the irradiation of near-infrared light, so that drugs are released as required, and precise treatment is realized. Besides, objective quantitative analysis of color signals is realized by constructing a convolutional neural network model, and the system has the functions of naked eye screening, intelligent quantification and personalized treatment, and can improve the home management ability of early skin cancer.

The invention discloses an exosome engineered targeted drug delivery system and a preparation method and application thereof, and belongs to the field of biomedices.The exosome engineered targeted drug delivery system is prepared by mixing and reacting surface modified exosome and pH response type drug controlled release nanoparticles; the pH response type drug controlled release nanoparticles react with the surface modified exosome through a click chemical reaction; the surface of the membrane of which the surface is modified with the exosome is modified with a maleimide group and an azide group; the novel nano-drug has pH responsiveness; the click chemical reaction is thiol-ene click reaction. Bifunctional groups (MAL and N3) are directionally grafted on the surface of an exosome membrane, uniform drug particles are prepared in combination with a micro-fluidic technology, an efficient bimodal targeting drug delivery system is successfully constructed, and remarkable technical advantages are shown in the aspects of improving targeting precision, enhancing antitumor activity, controlling drug release, inhibiting tumor metastasis and the like; and a new technical approach is provided for precise treatment of adenoid cystic carcinoma.

The present invention discloses a light-responsive Pickering emulsion that is synergistically stabilized by a spiropyran ionic liquid and UiO-66-NH2. The Pickering emulsion comprises an oil-water phase, and its stabilizer is a spiropyran ionic liquid and a metal-organic framework material UiO-66-NH2. The stable Pickering emulsion can undergo demulsification under additional visible light irradiation. When further irradiated with ultraviolet light, the system can be re-emulsified to form a stable Pickering emulsion. The Pickering emulsion provided by the present invention can be used for the Click reaction of hydrophilic azide compounds and terminal alkynyl compounds. Through reversible visible light and ultraviolet light regulation, the catalyst and spiropyran ionic liquid can be recycled, and the Pickering emulsion has application value in the fields of controlled drug release and sustainable catalysis.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

The present application discloses an antibacterial hydrogel dressing with integrated constant temperature photothermal effect and controlled drug release function, as well as its preparation method and application, which belongs to the field of medical biomaterial technology. The antibacterial hydrogel dressing with integrated constant temperature photothermal effect and controlled drug release function provided by the present application includes: a dressing and an antibiotic drug compounded on the dressing; the dressing is woven from photothermal water gel fiber and thermosensitive hydrogel fiber; the photothermal water gel fiber is made of photothermal dye, proton donor and phase change material as the core layer and sodium alginate as the shell layer; the thermosensitive hydrogel fiber is made of N-isopropyl acrylamide, methylene bisacrylamide, phenyl-2,4,6-trimethylbenzoyl lithium phosphinate and sodium alginate. The hydrogel dressing prepared by the present application has an inherent temperature control mechanism, can release drugs on demand and in a concentrated manner, has excellent antibacterial effect, and has broad application prospects in the preparation of biomedical materials.

The invention discloses a thiochromanone derivative containing a thiosemicarbazone structure and application of the thiochromanone derivative, relates to the technical field of medicines, and particularly relates to the technical field that the compound has better oxidation resistance and alpha-glucosidase resistance activity, the IC50 value of the compound 1-(7-chloro-4, 4-dioxothiochromanone-3-N-propyl) thiosemicarbazone to ABTS clearance activity is 2.86 [mu] g / mL, the IC50 value of the compound 1-(7-chloro-4, 4-dioxothiochromanone-3-N-propyl) thiosemicarbazone to alpha-glucosidase inhibition activity is 9.51 [mu] g / mL, and the effect is the best and is superior to that of a control agent vitamin E and acarbose. The thiochromanone derivative containing the thiosemicarbazone structure has a general formula shown in the specification,

The invention discloses ROS-responsive self-adhesive hydrogel and a preparation method and application thereof.The preparation method comprises the following steps that amine monomers, acid monomers, polyether and / or polyester, deionized water and an antioxidant are added into a high-pressure reaction kettle, the temperature is increased under the CO2 and / or inert atmosphere for a pressure maintaining reaction, then the temperature continues to be increased and vacuumized, and the ROS-responsive self-adhesive hydrogel is obtained; continuously reacting under a vacuum condition to obtain a polyamide elastomer; the preparation method comprises the following steps: dissolving a polyamide elastomer and a cross-linking agent I in deionized water, and reacting to obtain polyamide elastomer hydrogel; dissolving N-isopropylacrylamide, acrylic acid, a cross-linking agent II, an initiator, cerium oxide nanoparticles and silver nitrate in deionized water to obtain a prepolymer solution; the polyamide elastomer hydrogel is soaked in the prepolymer solution for polymerization, and the hydrogel is obtained. The hydrogel has a double-network structure, is good in biocompatibility, has temperature response and ROS response functions, and can control drug release and promote wound healing.

Intelligent control of patient-controlled drug delivery is disclosed. An infusion control device detects a patient-controlled drug request device in operable communication with the infusion control device. The infusion control apparatus identifies a sensor apparatus in operable communication with the infusion control apparatus and a drug delivery device separate from the infusion control apparatus. The infusion control device selects a drug control algorithm for approving a drug request received by a patient-controlled drug request device. The infusion control device identifies a patient using a patient-controlled drug request device and receives patient physiological data from a sensor device. The infusion control apparatus receives a request for a medicament to be delivered to a patient by a medicament delivery device. The infusion control device determines whether the patient is authorized to perform the medication request. And based on a determination that the patient is authorized, the infusion control device causes delivery of the medicament to the patient.

Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allow for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.

The invention relates to the technical field of patches, in particular to an intelligent temperature control medicine sustained release patch based on Mongolian medicine wrapping therapy and a preparation method thereof.The intelligent temperature control medicine sustained release patch comprises a flexible temperature control layer which comprises a graphene heating film, a miniature temperature control chip and a temperature sensor; the medicine slow release layer is connected with the flexible temperature control layer and comprises a medicine insertion groove and medicine-carrying hydrogel arranged in the groove; the breathable waterproof layer is connected with the drug sustained release layer and comprises a polyurethane porous membrane and a degradable non-woven fabric; the detection module is connected with the flexible temperature control layer and comprises a micro biosensor array arranged on the graphene heating film; the control module is respectively connected with the flexible temperature control layer and the detection module and is used for increasing the temperature of the graphene heating film when the drug release is judged to be unqualified according to the release performance characteristic value, or secondarily judging the eligibility of the drug release according to the change rate of the release rate. The treatment effect and the use convenience of the patch are improved.

Methods for treating an ear condition in a subject, comprising topically administering to the ear of the subject in need thereof a composition comprising: (i) an anti-infective agent-loaded biodegradable polymer microspheres; and (ii) a thermoresponsive hydrogel.

This invention arrests the hydrophilic silicone macrochains into semi-interpenetrating polymer network via in situ photo-gelation assisted 3D microextrusion printing technique. The printed hybrid hydrogel has shown microporous morphology with tunable diffusion behaviour. The flow behaviour of the hydrogel has been tested showing high elastic modulus, low tan δ, high gel strength, and delayed network rupturing behaviour. The uniaxial compression test showed the almost zero permanent set which could promote it as an elastomer mimetic soft biomaterial. Moreover, the drug loading into the hydrogel has been performed which showed hydrophilic silicone dependent non-Fickian anomalous transport. The encapsulated drug stability inside hydrogel matrices also showed no deterioration of the pristine drug molecules even after one month storage. This could be the first hydrodrophilic silicone based soft biomaterial will serve as an excellent controlled drug delivery device.